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Background: The purpose of this study was to evaluate gemcitab-
ine–carboplatin (GCb) versus single-agent gemcitabine (G) in pa-
tients with advanced non-small cell lung cancer (NSCLC) and a
performance status (PS) of 2. The primary endpoint was clinical
benefit.
Patients and Methods: Patients were randomly assigned to either
1250 mg/m2 of G (arm A) or 1250 mg/m2 of G plus carboplatin area
under the curve of 3 (arm B). Both treatments were given on days 1
and 14 and were repeated every 28 days for up to four cycles.
Results: Among the 90 eligible patients (47 in arm A and 43 in arm
B), in arm A, two (4%) had partial responses (95% CI, 0.52%–
14.5%) and 10 (21%) had stable disease (95% CI, 10.7%–35.7%). In
arm B, six (14%) had partial responses (95% CI, 5.3%–27.9%) and
nine (21%) had stable disease (95% CI, 10%–36%) (p  0.14). No
significant difference was found in terms of clinical benefit between
the two treatment groups after two cycles of treatment or at the end
of chemotherapy. Furthermore, no association was found between
clinical benefit and response to treatment (p  0.05). Median
survival was 4.8 months (95% CI, 2.45–7.25) for arm A and 6.7
months (95% CI, 2.47–10.8) for arm B (p  0.49). Neutropenia
(p  0.007) and thrombocytopenia (p  0.001) were more common
in group B. Nevertheless, no significant differences were found in
terms of severe toxicities (p  0.05 in all cases).
Conclusion: No significant difference was found in terms of clinical
benefit in patients with NSCLC and PS 2 who received single-agent
G or GCb. Nevertheless, GCb caused more toxicity, particularly
neutropenia and thrombocytopenia.
Key Words: Chemotherapy, Clinical benefit, Non-small cell lung
cancer, Performance status of 2, Gemcitabine, Carboplatin.
(J Thorac Oncol. 2007;2: 135–140)
The management of patients with advanced non-small celllung cancer (NSCLC) has improved during the last de-
cade. Compared with best supportive care, chemotherapy
offers improvement in overall survival and substantial palli-
ation,1–3 and a meta-analysis has shown that cisplatin-based
chemotherapy can prolong median survival by 1.5 months
and 1-year survival by 10%.4 This was improved further with
the addition of newer agents that was restricted to patients
with good performance status (PS).5–8
In several studies, a PS of 2 was proven to be the most
important negative prognostic factor.8–13
In the Eastern Cooperative Oncology Group (ECOG)
1594 and other trials, the final analysis proved that the
toxicity rate in patients with PS 2 did not differ significantly
from the PS 0 and 1 cohorts.12–14
As single agents, vinorelbine and gemcitabine (G) were
proven superior to best supportive care in median survival
and quality of life.15,16 Nevertheless, trials comparing single-
agent versus combination chemotherapy offered conflicting
results.17–19
Single-agent G has been used in elderly patients and
those with poor PS.15–17 The good toxicity profile and posi-
tive survival and quality-of-life results were the main reasons
our group used G as the control arm. Carboplatin (Cb) is an
accepted alternative to cisplatin, especially in patients who
cannot tolerate toxicity. We elected to use G with Cb (GCb)
as the experimental arm because of its good toxicity profile,
its known efficacy from trials with PS 0 and PS 1, and its
ease of administration through an outpatient setting.20 The
schedule and the doses of the given drugs were chosen to
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keep toxicity at the lowest level for this group of patients
with poor PS.
The primary endpoint of this study was clinical benefit,
which evaluated pain, cough, dyspnea, anorexia, hemoptysis,
fatigue, weight loss, and general feeling. Secondary end-
points were response, survival, time to disease progression
(TTP), and toxicity.
PATIENTS AND METHODS
Eligibility Criteria
Chemonaı¨ve patients were required to be at least 18
years of age with histologically confirmed, inoperable, recur-
rent, or metastatic stage IIIb NSCLC with pleural effusion or
stage IV NSCLC (American Joint Committee on Cancer
criteria21). An ECOG PS of 2 was required. Prior radiother-
apy was allowed. Patients were required to have completed
radiotherapy at least 4 weeks before chemotherapy and to
have a life expectancy of at least 12 weeks. Other require-
ments included measurable or assessable disease in nonirra-
diated fields, unless subsequent disease was documented.
Patients with stable brain metastases were eligible. In addi-
tion, patients must have had adequate bone marrow reserve,
kidney, and liver functions.
Patients with active infection or a history of other
neoplasms (except for basal cell carcinoma of the skin or in
situ carcinoma of the cervix) were excluded from the study.
Patients with active cardiac disease or preexisting grade 3 or
4 motor or sensory neuropathy (World Health Organization
[WHO] criteria22) were also excluded. Women of child-
bearing age were required to have a negative pregnancy test
within 48 hours of study enrollment.
The study was conducted in accordance with the ethical
principles stated in the most recent version of the Declaration
of Helsinki and the Hellenic Cooperative Oncology Group
institutional policies. All patients provided informed consent
before receiving study treatment.
Treatment Plan
Eligible patients were randomly assigned to either arm
A or arm B. Arm A received 1250 mg/m2 of G via 30-minute
infusion with normal saline on days 1 and 14. Group B
received the same G regimen plus Cb area under the curve of
3 (Calvert formula) as a 1-hour infusion on days 1 and 14. In
both arms, the treatment was repeated every 28 days for two
cycles; if patients had partial response, stable disease, or
clinical benefit, they received two more cycles. Reasons for
early discontinuation of treatment were progressive disease,
intolerable or unacceptable toxicity, and volunteer with-
drawal from the study. All patients received ondansentron as
an antiemetic.
If patients had hematologic toxicity (platelets 100,000/
mm3 and neutrophils 1500/mm3) or nonhematologic toxicity
grade 3/4 on the day of chemotherapy, their treatment was
postponed until recovery. If a delay was more than 15 days, the
patient was taken off the study. If patients had grade 3 or 4
toxicity, their doses were reduced by 25% for subsequent cycles.
If, after the first dose reduction, the grade 3 or 4 toxicity
persisted, then the patient was taken off the study.
Treatment Evaluation
All eligible patients who received at least two cycles of
chemotherapy were evaluated for efficacy. Using the intent-
to-treat principle, response was evaluated according to stan-
dard WHO criteria.22 All eligible patients who received at
least one cycle of chemotherapy were evaluable for toxicity.
Toxicity was evaluated according to WHO criteria.22
Evaluation of Clinical Benefit
The primary endpoint of this study was clinical benefit,
which was based on three measures. The first measure was
the Lung Cancer Symptom Scale, which consists of six
symptoms: dyspnea, cough, hemoptysis, fatigue, anorexia,
and pain; these symptoms were scored on a visual analogue
scale ranging from 0 to 100.23,24 The second measure was of
general feeling (very good, good, or poor), which was also
scored on a visual analogue scale ranging from 0 to 100. The
third measure was the patient’s weight (in light dress, without
shoes, and using a consistent scale).25–27 Along with the ana-
logue scale, patients reported improvement or worsening for
each scale item.
After randomization, patients were weighed and re-
corded their symptoms and general feeling on a special diary
card. After cycle 2, patients completed the visual analogue
scale of symptoms and general feeling, expressing the posi-
tive or negative changes during the last 4 weeks in compar-
ison with their baseline assessment. Their weight was also
recorded at this time. Similar procedures took place 2 weeks
after cycle 4, which was the end of treatment. In any case, all
new symptoms were recorded in the patient’s diary card.
Statistical Analysis
The sample size was calculated on the assumption that
a 0.6 standardized difference in clinical benefit existed be-
tween the two arms. For an alpha error of 0.05 and power of
80%, each arm needed to enroll 45 patients. The total number
of patients was estimated at 92, taking into consideration a
3% withdrawal rate. An interim analysis was not planned.
Overall survival was measured from the day of ran-
domization until death from any cause. Surviving patients
were censored on the day of the last contact. TTP was
measured from the day of randomization until the date pro-
gression of the disease was first documented.
Chi-square and Fisher’s exact tests were used to com-
pare major patient and tumor characteristics, symptoms be-
fore chemotherapy, and clinical benefit data between the two
arms. The Kaplan–Meier method was used to calculate over-
all survival and TTP curves, and the log-rank test was used to
compare time with event distributions.28 All of the analysis
was performed using SPSS system software, and in all cases
a p value of 0.05 (two tailed) was considered significant.
RESULTS
Baseline Patient Characteristics
From October 2000 to March 2003, 102 patients en-
tered this study. Two patients with incomplete medical
records were excluded from the analysis. Ten patients were
considered ineligible. Seven patients were inadvertently ran-
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domized (PS 2), two received protocol treatment as second
line, and one had another cancer.
Therefore, 90 eligible patients were analyzed in this
study. Forty-seven were allocated to arm A (G) and 43 to arm
B (GCb).
The baseline patient characteristics are presented in
Table 1.
Of the 90 eligible patients, 44 patients in arm A and 39
patients in arm B were included in the baseline clinical
benefit analysis. The baseline clinical benefit parameters of
weight loss and general feeling were well balanced between
arms (p  0.05 in all cases) (Table 2).
Response
In both arms, all patients were evaluable for efficacy. In
arm A, two patients (4%) had partial response (95% CI,
0.52%–14.5%) and 10 patients (21%) had stable disease
(95% CI, 10.7%–35.7%). In arm B, six patients (14%) had
partial response (95% CI, 5.3%–27.9%) and nine patients
(21%) had stable disease (95% CI, 10%–36%). There was no
statistical significance between the two arms (p  0.14).
Clinical Benefit Analysis
The main comparison regarding clinical benefit is based
on the general feeling parameter. The Lung Cancer Symptom
Scale parameters, because of the high rate of missing values,
are presented here mainly for descriptive purposes. Only
percent improvement by cycle is presented here, because of
the high missing value rate on the visual analogue scale for
the clinical benefit parameters. The clinical benefit analysis
after cycle 2 is shown in Table 3. No statistically significant
difference (p  1.0) was found between the two arms in
terms of general feeling after two cycles of treatment. Re-
garding symptoms, when compared with the baseline values,
each arm had improvement in all parameters except anorexia
(group A). Nevertheless, there is no significant difference
between the two arms (p  0.05 in all comparisons).
Twenty-three patients with partial or stable disease had
general feeling estimates after two cycles of treatment.
Among them, 16 (70%) reported an improvement. The re-
spective percentage among nonresponders was 60% (18 of 30
patients) (p  0.57).
Although fewer patients were assessed for clinical ben-
efit after cycle 4, there was still some improvement in some
of the symptoms (Table 3), although not significant (p 0.05
in all comparisons). General feeling at the end of treatment
did not differ significantly between the two arms (p  0.53).
At this stage, only 38 patients had data for general
feeling. Again, no association was found among those who
responded to chemotherapy and those who did not (58%
versus 36%, p 0.33) in terms of an improvement in general
feeling.
Time-to-Event Measures
After a median follow-up of 18.5 months (range, 0.1–
28), 74 patients (82%) had progressed (39 in group A and 35
in group B) and 72 (80%) had died (39 in group A and 33 in
group B). The median survival was 4.8 months (range,
0.1–18.8; 95% CI, 2.45–7.25) in group A and 6.7 months
(range, 0.1–28; 95% CI, 2.47–10.8) in group B (p  0.49)
(Figure 1). Furthermore, median TTP was 2.98 months
(range, 0.01–18.7; 95% CI, 2.26–3.71) in group A and 4.07
months (range, 0.01–28; 95% CI, 2.23–5.9) in group B (p 
TABLE 1. Baseline Patient and Tumor Characteristics
Gemcitabine Gemcitabine–Carboplatin
(Arm A, n  47) (Arm B, n  43)
Age (yr)
Median 73 70.5
Range 48–87 51–88
Gender, n (%)
Male 39 (83) 31 (72)
Female 8 (17) 12 (28)
Stage, n (%)
IIIb–IIIb wet 17 (36) 11 (26)
IV 30 (64) 32 (74)
Prior radiotherapy, n (%)
Yes 11 (23) 12 (28)
No 35 (75) 30 (70)
Unknown 1 (2) 2 (2)
Histology, n (%)
Squamous cell 13 (28) 13 (30)
Adenocarcinoma 27 (57) 24 (56)
Undifferentiated 4 (9) 4 (9)
Unclassified — 1 (2)
Unknown 3 (6) 1 (2)
Metastatic sites, n (%)
Lymph nodes 24 (51) 27 (63)
Pleural effusion 21 (45) 11 (26)
Liver 9 (19) 10 (23)
Bones 16 (34) 14 (33)
Brain 6 (13) 4 (9)
Adrenal glands 2 (4) 5 (12)
Number of metastatic
sites, n (%)
1 18 (38) 15 (35)
2 15 (32) 18 (42)
3 12 (26) 9 (21)
Unknown 2 (4) 1 (2)
TABLE 2. Baseline Clinical Benefit Assessments
Gemcitabine Gemcitabine–Carboplatin
(Arm A, n  44) (Arm B, n  39)
Assessment, n (%)
General feeling
Very good/good 19 (43) 19 (49)
Poor 25 (57) 20 (51)
Pain 17 (39) 18 (46)
Cough 22 (50) 20 (51)
Fatigue 27 (61) 23 (59)
Dyspnea 21 (48) 15 (38)
Anorexia 17 (39) 17 (44)
Hemoptysis 0 0
Weight loss 19 (43) 16 (41)
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0.36). The respective 1-year survival for group A and B was
17.8% and 20%, and the probability of being without pro-
gression beyond the first year was 10.6% for group A and
14.8% for group B.
Toxicity
Two patients in group A and one in group B did not
receive treatment and were thus excluded from toxicity anal-
ysis. Furthermore, two patients randomized in group B re-
ceived Gemzar only.
Overall, the treatments were well tolerated by both
arms. No toxic hospitalizations or deaths occurred during the
treatment period. Although neutropenia was more common in
group B (8.5% versus 32.5%, p  0.007), severe neutropenia
did not differ between the two groups (2% versus 7.5%, p 
0.33). Thrombocytopenia did not occur in arm A, but it
occurred in 10 patients (25%) in arm B (p  0.001). Severe
thrombocytopenia did not differ significantly between the two
treatment arms (0% versus 7.5%, p  0.09). Grade 3 anemia
was reported in one patient (2%) in arm A and in three
patients (7.5%) in arm B, a nonsignificant difference (p 
0.33). There were no instances of bleeding or infection.
Grade 3/4 nonhematologic toxicity was very rare in both
arms, without any significant difference.
Treatment Administration
A total of 292 cycles was administered in arm A and
242 cycles in arm B. In group A, 30 (64%) patients discon-
tinued their treatment, whereas 31 (72%) discontinued their
treatment in group B. The most common cause of discontin-
uation was disease progression (18 patients in group A versus
14 in group B). Additional reasons for treatment discontinu-
ation were death attributable to tumor (seven versus six),
voluntary withdrawal (four versus six), doctor’s decision (one
versus three), and other reasons (zero versus two). One
patient from group B died suddenly, after the first day of the
third cycle, from a cardiovascular accident, which was pos-
sibly unrelated to treatment or disease.
Significantly more cycles in group a were given at more
than 90% of the planned dose (86% versus 64%, p  0.001).
DISCUSSION
Patients with advanced NSCLC and PS 2 are a unique
group and have attracted the recent interest of investigators.
As an independent negative prognostic factor, PS 2 was
related to chemotherapy intolerability; thus, these patients
were excluded from clinical research and the potential benefit
TABLE 3. Clinical Benefit Analysis
Gemcitabine
(Arm A)
Gemcitabine–Carboplatin
(Arm B)
n
n
Improved % n
n
Improved % p
Clinical benefit after cycle 2
General feeling 28 18 64 26 17 65 1.0
Pain 15 10 67 17 9 53 0.49
Cough 18 11 61 17 10 59 1.0
Fatigue 20 11 55 18 11 61 0.75
Dyspnea 16 10 63 11 6 55 0.7
Anorexia 13 6 46 18 11 61 0.48
Weight loss 14 10 71 14 9 64 1.0
Clinical benefit after cycle 4
General feeling 21 11 52 17 7 41 0.53
Pain 7 3 43 8 4 50 1.0
Cough 13 9 69 7 5 71 1.0
Fatigue 12 7 58 8 4 50 1.0
Dyspnea 12 9 75 3 1 33 0.24
Anorexia 6 4 67 6 6 100 0.46
Weight loss 7 5 71 4 1 25 0.24
FIGURE 1. Effect of gemcitabine (solid line) and gemcitab-
ine–carboplatin (dashed line) on overall survival
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of chemotherapy in daily practice.8–13 A 2001 analysis of the
ECOG 1594 trial refuted this claim. The analysis of this trial
concluded that the shorter survival time was disease related
and not treatment related.14
The combination of G and Cb has known efficacy and
good toxicity profile in patients with NSCLC and PS 0 or 1.29
In our study, the toxicity was well tolerated in both arms, and
no toxic deaths occurred. Although the incidence of grade 3/4
toxicity was low in both arms, neutropenia (p  0.007) and
thrombocytopenia (p 0.001) were significantly worse in the
GCb arm compared with the G arm. Nevertheless, the lack of
serious infections and bleeding support the low toxicity
profile of both regimens, especially in this group of patients
in whom palliation and quality of life are the main goals.
Certainly, the low dose intensity of both drugs given to this
group of patients with poor PS explains the low toxicity.
Although the response rate was higher in the GCb arm
(14%) in comparison with the G arm (4%), the difference was
not statistically significant (p  0.14). Even when the re-
sponse rate was combined with stable disease (35% in the
GCb arm, 25% in the G arm), the difference was not statis-
tically significant between the two arms (p  0.36). For
time-to-event measures, there were no statistically significant
differences in survival (p  0.49), TTP (p  0.36).
The comparison with other similar trials is interesting.
In the MILES phase III trial,17 the comparison vinorelbine–G
was associated with more thrombocytopenia and hepatotox-
icity than with single-agent vinorelbine and with more neu-
tropenia, vomiting, fatigue, extravasation sequellae, cardio-
toxicity, and constipation than with single-agent G. Measures
of quality of life were similar in all arms.
In the subanalysis of the CALGB 9730 phase III trial,
of 99 patients with PS 2, the median survival (4.7 versus
2.4 months) and 1-year survival (18% versus 10%) were
statistically significant in favor of the combination pacli-
taxel–Cb.19
In another approach, an ECOG trial (E1599)30 evalu-
ated two combination regimens: 200 mg/m2 of paclitaxel and
Cb area under the curve of 6 mg/mL per minute every 3
weeks versus 1000 mg/m2 of G on days 1 and 8 and 60
mg/m2 of cisplatin on day 1. Disease-control rates, median
survival, and TTP were similar in both arms. Thrombocyto-
penia was more pronounced in the cisplatin–G arm, whereas
neurotoxicity was more common in the paclitaxel–Cb arm.
The clinical benefit analysis cannot substitute for qual-
ity-of-life measurement. There is a distinction between the
two assessments, and clinical benefit is part of the overall
quality of life of patients. It is also known that improvement
of clinical benefit may have a modest impact on overall
quality of life.31 Nevertheless, in this group of patients with
poor performance status, short survival, very limited social
activity, low response rate, and increased progressive disease,
frequent assessments are difficult, and the dropout rate is
high. Also, the amount of missing data in a multiple-endpoint
instrument, combined with small group of patients, may
jeopardize the results. Our group considered these reasons
when we elected to use the clinical benefit as the symptomatic
dimension of quality of life.
In our study, the majority of patients who answered the
clinical benefit questionnaire had improvements of symptoms
and general feelings after cycle 2. The difference of this
improvement between the two arms was not statistically
significant. By the end of cycle 4, the majority of patients
(52%) in arm A had continued improvements in general
feelings, and a minority of patients (41%) in arm B further
improved (p  0.53). Nevertheless, the number of patients at
that point was small, and the decreasing improvement in the
arm B cannot be precisely related to disease progression or
chemotherapy toxicity.
The clinical benefit for patients with NSCLC and PS 2
that has been reported in other studies is consistent with our
findings.16,26,27,32 Nevertheless, in our trial, combination che-
motherapy was not proven superior to single-agent chemo-
therapy in terms of response, survival, or clinical benefit, and
it was proven more toxic.
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